Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline PRAGUE & AMSTERDAM--(BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage ...

As the oncology landscape evolves, antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in ...

Zymeworks has outlined its strategic priorities for 2026 following what it describes as a transformative 2025 marked by positive late-stage clinical data, regulatory wins, and expanding collaborations ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

Tubulis today announced the appointment of Charles Fuchs, MD, as Chief Medical Officer (CMO). Dr. Fuchs is an internationally ...

MUNICH, Germany--(BUSINESS WIRE)--Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life ...

Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on ADC Therapeutics (ADCT – Research Report). The associated price target was raised to $10.00. Naureen Quibria has ...

-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin ...

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- ...

SAN DIEGO, CA, UNITED STATES, January 5, 2026 /EINPresswire.com/ — Silanna Semiconductor today announced it has integrated a feature-rich DSP into its Plural™ family of high-speed, low-power ADCs. All ...

PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...